IN8BIO, INC Share Price Today: Live Updates & Key Insights

IN8BIO, INC share price today is $2.04, up 16.28%. The stock opened at $1.7 against the previous close of $1.72, with an intraday high of $2.01 and low of $1.7.

IN8BIO, INC Share Price Chart

IN8BIO, INC

us-stock
To Invest in {{usstockname}}
us-stock

IN8BIO, INC Share Price Performance

$2.04 0.1628(16.28%) INAB at 23 Mar 2026 01:39 PM Biotechnology
Lowest Today 1.7
Highest Today 2.01
Today’s Open 1.7
Prev. Close 1.72
52 Week High 7.20
52 Week Low 1.17
Day’s Range: Low 1.7 High 2.01
52-Week Range: Low 1.17 High 7.20
1 day return -
1 Week return -3.5
1 month return +27.81
3 month return +24.11
6 month return -8.96
1 year return +753.98
3 year return +60.83
5 year return -80.7
10 year return -

IN8BIO, INC Institutional Holdings

Alyeska Investment Group, L.P. 9.80

683 Capital Management LLC 7.42

Franklin Biotechnology Discv A(acc)USD 5.96

Franklin Biotechnology Discovery A 3.40

BIOS CAPITAL MANAGEMENT, LP 2.59

Franklin Resources Inc 1.94

Stonepine Capital Management Llc 1.69

Two Sigma Advisers, LLC 0.37

Vanguard Group Inc 0.29

Two Sigma Investments LLC 0.29

Geode Capital Management, LLC 0.21

Vanguard Institutional Extnd Mkt Idx Tr 0.20

DRW Securities, LLC 0.19

CapTrust Financial Advisors 0.19

HRT FINANCIAL LLC 0.15

NT Ext Equity Mkt Idx Fd - L 0.14

Fidelity Extended Market Index 0.13

XTX Topco Ltd 0.13

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.05

Northwestern Mutual Wealth Management Co 0.03

Spartan Total Market Index Pool G 0.03

Fidelity Series Total Market Index 0.03

Tower Research Capital LLC 0.03

Northern Trust Extended Eq Market Idx 0.02

Fidelity Total Market Index 0.02

NT Ext Equity Mkt Idx Fd - NL 0.01

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.01

Vanguard Instl Ttl Stck Mkt Idx Tr 0.01

Fidelity Nasdaq Composite Index 0.01

Blackstone Alternative Multi-Strategy I 0.01

State St US Extended Mkt Indx NL Cl C 0.00

BlackRock Inc 0.00

Rockefeller Capital Management L.P. 0.00

Citigroup Inc 0.00

Northern Trust Wilshire 5000 0.00

NT US Market Cap Idx Fd - L 0.00

Bank of America Corp 0.00

UBS Group AG 0.00

Fidelity U.S. Equity Index Ins Trust 0.00

Vanguard Total Stock Mkt Idx Inv 0.00

IN8BIO, INC Market Status

Strong Buy: 2

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

IN8BIO, INC Fundamentals

Market Cap 19.69 M

PB Ratio 0.6095

PE Ratio 0.0

Enterprise Value -5.06 M

Total Assets 32.28 M

Volume 254382

IN8BIO, INC Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:-2501000 -2.5M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-30007000 -30.0M, FY22:-27418000 -27.4M, FY21:-14653000 -14.7M, FY20:-8557000 -8.6M, FY19:-5134000 -5.1M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-498000 -0.5M, Q1/2025:-429000 -0.4M, Q3/2024:null 0.0M, Q2/2024:-631000 -0.6M

Quarterly Net worth Q3/2025:-3854000 -3.9M, Q2/2025:-5094000 -5.1M, Q1/2025:-5550000 -5.6M, Q3/2024:-7086000 -7.1M, Q2/2024:-8629000 -8.6M

About IN8BIO, INC & investment objective

Company Information IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer; and INB-600, a gamma-Delta T cell engager. In addition, it is developing INB-619, a gamma-delta TCE targeting CD19 for potential applications in both oncology and autoimmune diseases. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Organisation Biotechnology

Employees 17

Industry Biotechnology

CEO Mr. Tai-Wei Ho

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

IN8BIO, INC FAQs

What is the share price of IN8BIO, INC today?

The current share price of IN8BIO, INC is $2.04.

Can I buy IN8BIO, INC shares in India?

Yes, Indian investors can buy IN8BIO, INC shares by opening an international trading and demat account with Motilal Oswal.

How to buy IN8BIO, INC shares in India?

You can easily invest in IN8BIO, INC shares from India by:

Can I buy fractional shares of IN8BIO, INC?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of IN8BIO, INC?

IN8BIO, INC has a market cap of $19.69 M.

In which sector does IN8BIO, INC belong?

IN8BIO, INC operates in the Biotechnology sector.

What documents are required to invest in IN8BIO, INC stocks?

To invest, you typically need:

What is the PE and PB ratio of IN8BIO, INC?

The PE ratio of IN8BIO, INC is N/A and the PB ratio is 0.61.